Fate Therapeutics (FATE) to Release Earnings on Wednesday

Fate Therapeutics (NASDAQ:FATE) is projected to issue its Q4 2025 results before the market opens on Wednesday, March 4th. Analysts expect Fate Therapeutics to post earnings of ($0.27) per share and revenue of $1.1980 million for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, March 5, 2026 at 4:00 PM ET.

Fate Therapeutics Stock Performance

FATE stock opened at $1.62 on Wednesday. The firm has a market cap of $186.87 million, a P/E ratio of -1.23 and a beta of 2.24. Fate Therapeutics has a 1 year low of $0.66 and a 1 year high of $1.94. The stock has a 50-day simple moving average of $1.15 and a 200-day simple moving average of $1.15.

Analyst Ratings Changes

Several analysts have issued reports on FATE shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Fate Therapeutics in a research report on Thursday, January 22nd. HC Wainwright upgraded shares of Fate Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 target price for the company in a research note on Friday, October 31st. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Fate Therapeutics in a research note on Tuesday, November 4th. Finally, Wall Street Zen lowered shares of Fate Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Three investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $3.92.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Commonwealth Equity Services LLC bought a new stake in shares of Fate Therapeutics in the 4th quarter worth about $26,000. Bridgeway Capital Management LLC acquired a new position in Fate Therapeutics in the second quarter worth about $28,000. Corient Private Wealth LLC bought a new stake in Fate Therapeutics in the fourth quarter valued at about $29,000. The Manufacturers Life Insurance Company acquired a new stake in Fate Therapeutics during the fourth quarter valued at approximately $35,000. Finally, Russell Investments Group Ltd. raised its stake in Fate Therapeutics by 73.1% during the third quarter. Russell Investments Group Ltd. now owns 28,676 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 12,114 shares in the last quarter. 97.54% of the stock is currently owned by institutional investors.

About Fate Therapeutics

Fate Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of first‐in‐class cellular immunotherapies for cancer and immune disorders. The company leverages its proprietary induced pluripotent stem cell (iPSC) platform to create off‐the‐shelf natural killer (NK) and T‐cell products designed to overcome limitations of donor‐derived approaches. Fate’s research aims to deliver therapies with consistent quality, increased potency and scalable manufacturing for broad patient access.

Central to Fate’s pipeline are multiple iPSC‐derived cell therapy candidates in active clinical development.